- Trials with a EudraCT protocol (102)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
102 result(s) found for: Radiation intensity.
Displaying page 1 of 6.
EudraCT Number: 2009-014441-93 | Sponsor Protocol Number: X-03030-3277 | Start Date*: 2010-08-16 | |||||||||||
Sponsor Name:MEDA Pharma GmbH & Co. KG | |||||||||||||
Full Title: Clinical trial to assess the efficacy of the fixed combination product Tepilta® in the treatment of radiation-induced oesophagitis compared to its active ingredients oxetacaine and antacids, and t... | |||||||||||||
Medical condition: Radiation-induced oesophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000163-26 | Sponsor Protocol Number: HS-05-161 | Start Date*: 2008-08-01 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A randomised, two-period cross-over, multicentre, double-blind, single-dose, placebo-controlled study to assess the local analgesic effect of CAM2028 in head-and-neck cancer patients suffering from... | |||||||||||||
Medical condition: Head-and-neck cancer patients suffering from radiation-indused oral mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017943-32 | Sponsor Protocol Number: 871 | Start Date*: 2010-05-31 | |||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||
Full Title: Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer | |||||||||||||
Medical condition: Histologically confirmed squamous cell carcinoma of the head and neck which qualifies for definitive treatment with chemoradiation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001271-20 | Sponsor Protocol Number: MOLT-2013-02 | Start Date*: 2013-08-12 | |||||||||||
Sponsor Name:L. Molteni & C dei F.lli Alitti Società di Esercizio S.p.A. | |||||||||||||
Full Title: A multicenter randomized open trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pa... | |||||||||||||
Medical condition: Patients with head and neck cancer undergoing radiotherapy with uncontrolled pain at swallowing (moderate/severe intensity). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001534-13 | Sponsor Protocol Number: JAN13004-30 | Start Date*: 2015-10-02 | |||||||||||
Sponsor Name:SPHERIUM BIOMED S.L. | |||||||||||||
Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation. | |||||||||||||
Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005126-35 | Sponsor Protocol Number: GBG86-DESIREE | Start Date*: 2015-06-03 | ||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | ||||||||||||||||||
Full Title: A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer | ||||||||||||||||||
Medical condition: Advance Breast cancer under endocrine treatment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001554-33 | Sponsor Protocol Number: BGB-290-104 | Start Date*: 2018-01-24 |
Sponsor Name:BeiGene USA, Inc. | ||
Full Title: A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma | ||
Medical condition: glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000833-40 | Sponsor Protocol Number: CCR4502 | Start Date*: 2016-10-07 |
Sponsor Name:The Institute of Cancer Research | ||
Full Title: Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of... | ||
Medical condition: Women with locally advanced/recurrent breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003702-41 | Sponsor Protocol Number: IDR-OM-02 | Start Date*: 2018-07-03 |
Sponsor Name:Soligenix UK Limited | ||
Full Title: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for... | ||
Medical condition: Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) ES (Completed) HU (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005278-86 | Sponsor Protocol Number: 147(Z)WO20157 | Start Date*: 2021-06-14 | ||||||||||||||||
Sponsor Name:AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. | ||||||||||||||||||
Full Title: Efficacy and safety of the combination of ibuprofen and paracetamol versus ibuprofen in monotherapy in acute Low Back Pain (LBP) | ||||||||||||||||||
Medical condition: Low Back Pain (LBP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002745-38 | Sponsor Protocol Number: GTI-4419-202 | Start Date*: 2020-01-16 | |||||||||||
Sponsor Name:Galera Therapeutics, Inc. | |||||||||||||
Full Title: An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated with Chemorad... | |||||||||||||
Medical condition: Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004189-14 | Sponsor Protocol Number: 24061 | Start Date*: 2008-02-13 |
Sponsor Name:EORTC | ||
Full Title: Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies | ||
Medical condition: Histologically proven newly diagnosed unresectable squamous cell carcinoma of the head and neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) HU (Completed) NL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005219-98 | Sponsor Protocol Number: PH3-01 | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Galena Biopharma, Inc | |||||||||||||
Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT) | |||||||||||||
Medical condition: Operable early-stage, node-positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009857-17 | Sponsor Protocol Number: 42160443PAI2003 | Start Date*: 2009-12-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequate... | |||||||||||||
Medical condition: Moderate to severe, chronic, low back pain (LBP) that is not adequately controlled by standard pain therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000741-36 | Sponsor Protocol Number: 07_DOG08_29 | Start Date*: 2007-06-18 |
Sponsor Name:Christie Hospital NHS Trust | ||
Full Title: Study of radiotherapy dose escalation with Intensity Modulated Radiation Therapy (IMRT) and synchronous Cetuximab for intermediate stage head and neck cancer | ||
Medical condition: Intermediate Stage (TNM Stage II/Stage III) Head and Neck Squamous Cell Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005835-87 | Sponsor Protocol Number: GBG41 | Start Date*: 2006-08-16 |
Sponsor Name:GermanBreastGroup | ||
Full Title: A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases | ||
Medical condition: Bone metasatsis, Breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000182-10 | Sponsor Protocol Number: CBI-GBM-01 | Start Date*: 2006-05-04 |
Sponsor Name:Rigshospitalet, Finsen Center | ||
Full Title: A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid | ||
Medical condition: Recurrent or progressive primary GBM in patients with performance status (PS) 0-2. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001065-21 | Sponsor Protocol Number: ET21-023 | Start Date*: 2021-10-12 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) | |||||||||||||
Medical condition: Locally advanced or metastatic papillary cell carcinoma (PRCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016489-10 | Sponsor Protocol Number: TPF-C-HIT | Start Date*: 2010-08-23 |
Sponsor Name:University of Heidelberg | ||
Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc... | ||
Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001963-37 | Sponsor Protocol Number: PemSplitCisp_03-11 | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC) | |||||||||||||
Medical condition: Advanced and inoperable Non-sqamous Non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
